Clearant, Inc.
HCID Member | Biotech Specialty Pharma
1801 Avenue of the Stars, Suite 435
Los Angeles, CA 90067 USA
phone: 310-479-4570
fax:
Symbol CLRA
Exchange .OB
Founded 1999
Employees 7
www.clearant.com
Research Sector Biotech Specialty Pharma
Summary Description
Pathogen inactivating technology for the reduced contamination of biological products
Management
Jon M. Garfield, Chief Executive Officer
Susan Etzel, CFO
Ownership
Financials Mkt Cap :6


* numbers in thousands

Recent Results
For the first quarter ended March 2006, revenues increased 78% to $190,000. The net loss for the quarter was $2,513 compared to a loss of $3,100 for the first quarter of 2005.
 
Keywords
pathogen inactivation technology, tissue allograft implants, plasma therapies, blood products, recombinant products, sterilization

Comment | Printable Version | Jan. 03, 2009
If you work for Clearant, Inc. and want to update this profile, click here

Description
Clearant Corporation, a biotechnology company, develops and markets pathogen inactivation technology. The Clearant Process reduces the risk of contamination of biological products.
Products / Services
The Clearant Process substantially inactivates all types of known pathogens for products across a variety of market segments, including plasma therapies, tissue allograft implants, recombinant products and blood products.
Technology / Differentiation
The Clearant Process is based on gamma-irradiation technology that delivers a predetermined amount of radiation to inactivate a desired level of pathogens. This process reduces the risk of contamination while preserving the functionality and integrity of the treated product. The Process is used in both intermediate and final stages of production and can be applied to products after they have been sealed.
Market / Customers
Two million Americans undergo orthopedic and spinal surgeries that could be made safer with the company's technology. The Process is intended to address safety concerns regarding allografts and certain other biological products. The Clearant process is marketed to tissue banks, pharmaceutical and biotechnology companies.
Strategy
Clearant will continue to add license agreement in its existing markets. Additionally, Clearant intends to generate recurring revenues from irradiation services. In September 2005, Clearant launched a new sterilization service which allows tissue banks to send ready for sterilization tissue to their facility to irradiated by Clearant.
Status
In February 2008, Clearant announced that it had been selected by Millennium Surgical Center of Cherry Hill, New Jersey, as its primary source of allograft tissue for use in reconstructive knee surgery. To date, Clearant has signed 11 license agreements with customers to utilize the Clearant Process with its products.


2009-01-07-1971